Email updates

Keep up to date with the latest news and content from Pediatric Rheumatology and BioMed Central.

This article is part of the supplement: 2011 Pediatric Rheumatology Symposium: Abstracts

Open Access Open Badges Poster presentation

Neuroblastoma versus systemic JIA – a diagnostic dilemma

Lisabeth Scalzi4*, Greg Hychko2, Barbara E Ostrov1, Catherine A Bingham3, David Ungar1 and Brandt P Groh1

  • * Corresponding author: Lisabeth Scalzi

Author Affiliations

1 Hershey Medical Center, Hershey, PA, USA

2 Indiana University, Bloomington, IN, USA

3 Zionsville, PA, USA

4 Pennsylvania State University/Hershey, Hershey, PA, USA

For all author emails, please log on.

Pediatric Rheumatology 2012, 10(Suppl 1):A33  doi:10.1186/1546-0096-10-S1-A33

The electronic version of this article is the complete one and can be found online at:

Published:13 July 2012

© 2012 Scalzi et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Children with malignancies, including neuroblastoma (NB), may present to their primary physician with complaints that mimic those seen in systemic juvenile idiopathic arthritis (sJIA). The purpose of this investgation was to identify significant distinctions between patients with systemic JIA and neuroblastoma at the time of disease presentation.


A retrospective chart review was completed on all patients less than age 18, between 1990 and 2009 at Pennsylvania State University Children’s Hospital, with a diagnosis of either sJIA or NB. The following variables were identified at the time of presentation; gender, age, race, time to diagnosis, presenting signs and symptoms, neuroblastoma stage, LDH, uric acid, sedimentation rate, CRP, platelet count, hemoglobin, peripheral white blood cell count, percentage of neutrophils and lymphocytes, ferritin, and d-dimer. Other categorical information included whether or not the patients had gait disturbance or extremity pain, fever, rash, abdominal mass, arthritis, fatigue, or weight loss. Individual logistic regression models were evaluated for each variable, with sJIA or NB as the outcome. Given that patients with NB and extremity pain may be referred to orthopedics or rheumatology first, instead of a timely referral to hematology/oncology, a subgroup analysis was completed for those patients.


There was a total of 65 sJIA and 89 NB patients. Demographically, sJIA patients were significantly older (7.2 vs. 3.0 years of age; p<0.0001). Symptomatically, the sJIA patients had fever, rash,arthritis, and extemity pain or gait disturbance (41% vs. 18%) more frequently (p<0.0001 for all). Laboratories were also significantly different between the groups. NB patients had higher LDH and uric acid levels, while sJIA patients had higher platelet counts, total peripheral WBC, had relative neutrophilia (p<0.0001 for all), and had higher ferritin levels than the NB patients (p=0.001), see Table 1. In the subgroup of 58 children with extremity pain or gait disturbance, 45 (78%) had sJIA and 13 (22%) had NB; see Table 2. NB patients had higher LDH (p=0.01) and lower hgb levels (p=0.003), while sJIA patients had a relative neutrophilia (76% versus 51%; p<0.0001).

Table 1. Presentation characteristics of SJIA versus NB patients

Table 2. Laboratory values for sJIA and NB subjects with gait disturbance or extremity pain


There are significantly different demographic, presenting symptoms, and laboratories at the time of presentation of patients who are ultimately diagnosed with sJIA or NB. In particular, there are discerning laboratories that may help facilitate an appropriate and timely referal to oncology when extremity pain or gait disturbance are among the intial signs and symptoms.


Lisabeth Scalzi: None; Greg Hychko: None; Barbara E. Ostrov: None; Catherine A. Bingham: None; David Ungar: None; Brandt P. Groh: None.